Patient characteristics at enrollment
| Characteristics | No. of patients (%) | P | |
|---|---|---|---|
| SVILE (n = 52) | P-GemOx (n = 51) | ||
| Male | 34 (65.4) | 34 (66.7) | 0.891 |
| Age, median (range, years) | 46 (18–63) | 47 (18–67) | 0.368 |
| B-symptoms present | 41 (78.8) | 33 (64.7) | 0.111 |
| †PET/CT at diagnosis | 51 (98.1)a | 51 (100) | 1.000 |
| ‡SUVmax, mean ± SD | 11.727 ± 5.945 | 13.747 ± 7.232 | 0.117 |
| Lymph node involvement | 18 (34.6) | 15 (29.4) | 0.571 |
| Nasal involvement | 52 (100) | 50 (98.0)a | 0.495 |
| Decreased serum album | 19 (36.5) | 13 (25.5) | 0.226 |
| Elevated serum §LDH | 12 (23.1) | 13 (25.5) | 0.775 |
| Elevated serum ¶β-2 MG | 28 (53.8) | 24 (47.1) | 0.491 |
| Ann Arbor stage | |||
| I/II | 36 (69.2) | 33 (64.7) | 0.625 |
| III/IV | 16 (30.8) | 18 (35.3) | |
| PINK grade | |||
| Low | 25 (48.1) | 24 (47.1) | 0.258 |
| Intermediate | 18 (34.6) | 12 (23.5) | |
| High | 9 (17.3) | 15 (29.4) | |
| ¥-IFRT | 45 (86.5) | 46 (90.2) | 0.563 |
†PET/CT, positron emission tomography/computed tomography; ‡SUV, standard uptake value; §LDH, lactate dehydrogenase; ¶β2 MG, beta-2 microglobulin; ¥-IFRT, involved-field radiotherapy; aFisher test was used when n < 5.